Evidence map›Paper›PMID 35137271›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2022

Role of CSE1L expression in determining recurrence and survival of laryngeal tumors.

Tuncay Tunccan, Caner Kılıc, Arzu Betul Duran, Samet Ozlugedik, Ayca Ant, Gökberk Alkan

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tuncay TunccanDepartment of Ear Nose and Throat, Oncology Training and Research Hospital, Onkoloji Hastanesi, Demetevler, 06200, Ankara, Turkey. ttunccan@gmail.com.ORCID http://orcid.org/0000-0003-3321-5772
Caner KılıcDepartment of Ear Nose and Throat, Oncology Training and Research Hospital, Ankara, Turkey.ORCID http://orcid.org/0000-0003-2879-2524
Arzu Betul DuranDepartment of Ear Nose and Throat, Oncology Training and Research Hospital, Ankara, Turkey.ORCID http://orcid.org/0000-0002-4121-7439
Samet OzlugedikDepartment of Ear Nose and Throat, Oncology Training and Research Hospital, Ankara, Turkey.ORCID http://orcid.org/0000-0001-7909-9100
Ayca AntDepartment of Ear Nose and Throat, Oncology Training and Research Hospital, Ankara, Turkey.ORCID http://orcid.org/0000-0002-9469-1468
Gökberk AlkanDepartment of Ear Nose and Throat, Oncology Training and Research Hospital, Ankara, Turkey.ORCID http://orcid.org/0000-0001-5737-3455
Ministry of Health · TRAnkara Onkoloji Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe correlation of CSE1L (human chromosomal segregation 1-like) staining intensity with disease-free survival, disease recurrence and development of distant metastases in Advanced Laryngeal Tumors.

methodsSpecimens of patients with advanced glottic larynx cancer (T3, T4) were evaluated for nuclear CSE1L staining intensity. According to mild, moderate and severe CSE1L staining, patients were compared in terms of disease-free survival, disease recurrence and development of distant metastases.

results17 of the 57 patients died within 5 years, distant metastases developed in 5 patients, and recurrence in 5 patients. Of the 17 patients who died within 5 years, 10(%59) showed severe staining with CSE1L, 6 (%35) showed moderate staining, and only 1 (%6) patient showed mild staining. 4 (%80) out of 5 patients who developed distant metastases were those with moderate staining with CSE1L. Metastases did not develop in any patient who stained poorly with CSE1L. 2 (%40) of the 5 patients who developed relapse were patients with severe staining with CSE1L, while 3 (%60) were patients with moderate staining with CSE1L. No recurrence was observed in any patient with mild staining with CSE1L.

conclusionCSE1L will help in demonstrating the increased risk of distant metastasis, increased recurrence probability and shortened life expectancy of advanced laryngeal carcinoma.

Indexed as

CarcinomaLaryngeal NeoplasmsLarynxDisease-Free SurvivalGlottisHumansNeoplasm Recurrence, LocalCSE1LDisease-free survivalLarynx cancer

Identifiers

PMID35137271
OpenAlexW4210882782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.